PD-L1 expression in peripheral blood samples of patients with oral squamous cell carcinomas (2018) Ries J, Weber M, Baran C, Agaimy A, Buettner-Herold M, Preidl R, Neukam FW, Wehrhan F Conference contribution Multidisciplinary Late Effects Clinics for Childhood Cancer Survivors in Germany - a Two-Center Study (2018) Gebauer J, Rieken S, Schuster S, Hahn B, Gebauer N, Meidenbauer N, Brabant G, et al. Journal article Potential role of the PD-1/PD-L1 axis in the immune regulation of chronic GVHD (2017) Klobuch S, Weber D, Holler B, Herr W, Holler E, Wolff D Journal article Prognostic factors for overall survival of patients with advanced renal cell carcinoma - data from the German prospective RCC-Registry (2017) Goebell P, Mueller L, Staehler M, Mueller M, Frank M, Kruggel L, Jaenicke M, Marschner N Conference contribution Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study (2017) Bedke J, Welslau M, Boegemann M, Schostak M, Hering-Schubert C, Petzoldt A, Wolf T, et al. Conference contribution RECREATE - A retrospective chart review to assess the treatment reality for mRCC patients following 1st line Pazopanib: reflecting a changing mRCC treatment landscape (2017) Hegele A, Van Der Heyde E, Goebell P, Zengerling F, Hbner A, Klier J, Belz H, et al. Conference contribution Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer (2017) Fasching P, Fernandez Abad M, Garcia-Saenz JA, Schneeweiss A, Guarneri V, Colleoni M, Petru E, et al. Conference contribution Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma - data from the German prospective RCC-Registry (2017) Staehler M, Goebell P, Mueller L, Overkamp F, Frank M, Kruggel L, Jaenicke M, Marschner N Conference contribution Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome (2017) Pavel ME, Gable J, Kulke MH, Bergsland E, Anthony LB, Caplin ME, Oberg KE, et al. Conference contribution Bevacizumab (Bev)-based combinations across treatment lines in patients (pts) with metastatic colorectal cancer (mCRC) - interim results from a German non-interventional study (KORALLE) (2017) Eggers E, Uhlig J, Reichert D, Wein A, Schulz H, Beringer A, Arnold D Conference contribution